Gilead exercises option for Kymera's cancer drug candidate KT-200
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq drops as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
April 9, 2026 7:01 AM EDTKT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidateÂ
Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences
WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced that Gilead Sciences, Inc. has exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue... More
